Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Cash (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Change in Cash for 10 consecutive years, with $221.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash rose 815.69% to $221.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $252.0 million, a 820.0% increase, with the full-year FY2025 number at $252.0 million, up 820.0% from a year prior.
  • Change in Cash was $221.5 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $26.1 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $367.9 million in Q2 2024 to a low of -$330.0 million in Q3 2024.
  • A 5-year average of -$14.5 million and a median of -$11.3 million in 2022 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 2179.24% in 2024; the steepest drop was 1035.71% in 2024.
  • Ultragenyx Pharmaceutical's Change in Cash stood at $100.0 million in 2021, then tumbled by 358.59% to -$258.7 million in 2022, then skyrocketed by 154.11% to $140.0 million in 2023, then tumbled by 82.72% to $24.2 million in 2024, then surged by 815.69% to $221.5 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Change in Cash are $221.5 million (Q4 2025), $26.1 million (Q3 2025), and $49.5 million (Q2 2025).